Revvity Q2 revenue beats estimates on diagnostics growth

Revvity

04/08/2026 11:20

Overview
Health science solutions provider's Q2 revenue rose 4%, beating analyst expectations
Q2 adjusted EPS was $1.41, above analyst consensus
Company to divest China Immunodiagnostics business, representing about 6% of 2025 revenue

Outlook
Revvity raises full-year 2026 guidance for pro forma revenue to $2.83-$2.86 bln
Company expects 2026 pro forma organic revenue growth of 4-5%
Revvity forecasts 2026 pro forma adjusted EPS of $5.30-$5.40

Result Drivers
DIAGNOSTICS SEGMENT GROWTH - Diagnostics segment pro forma organic revenue rose 11% and adjusted operating profit margin improved, driving overall results
TARIFF REFUNDS - Tariff-related refunds contributed $16 mln to operating income and about $0.11 to adjusted EPS
LIFE SCIENCES SEGMENT DECLINE - Life Sciences segment pro forma organic revenue fell 3% and adjusted operating profit margin declined

Company press release: ID:nBw3gbVZra

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$730 mln
$709.11 mln (14 Analysts)
Q2 Adjusted EPS
Beat
$1.41
$1.22 (15 Analysts)
Q2 Adjusted EPS continuing operations
 
$1.41
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Revvity Inc is $120.00, about 4.1% above its August 3 closing price of $115.22
The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)